Actuate Therapeutics (ACTU) Accumulated Expenses (2023 - 2025)

Actuate Therapeutics (ACTU) has reported Accumulated Expenses for 3 consecutive years, with $27018.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Expenses fell 96.96% year-over-year to $27018.0; the TTM figure through Dec 2025 stood at $27018.0 (down 96.96% YoY), while the FY2025 annual figure was $27018.0, down 96.96% from the prior year.
• Accumulated Expenses declined to $27018.0 in Q4 2025 per ACTU's latest filing, from $4.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.1 million in Q3 2024 and bottomed at $27018.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $2.7 million across 3 years, with a median of $2.3 million in 2023.
• On a YoY basis, Accumulated Expenses climbed as much as 400.22% in 2025 and fell as far as 96.96% in 2025.
• Actuate Therapeutics' Accumulated Expenses stood at $3.2 million in 2023, then slumped by 72.42% to $888449.0 in 2024, then sank by 96.96% to $27018.0 in 2025.
• Business Quant data shows ACTU's Accumulated Expenses at $27018.0 in Q4 2025, $4.3 million in Q3 2025, and $1.4 million in Q2 2025.